Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Proteomic profiling of bone marrow in AML

Christopher Hourigan • 16 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, describes a novel proteomic approach to characterize the non-cellular compartment of the bone marrow microenvironment in acute myeloid leukemia (AML) and outlines how this provides mechanistic insights into AML etiology as well as guiding efforts in future targeted therapies and immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Christopher Hourigan

Improving transplant outcomes in AML
Improving transplant outcomes in AML
Charles Craddock et al. • 12 Apr 2023
The importance of measurable residual FLT3-ITD before alloSCT for AML
1:33
The importance of measurable residual FLT3-ITD before alloSCT for AML
Christopher Hourigan • 4 Sep 2024
Determining complete remission in patients with AML
1:18
Determining complete remission in patients with AML
Christopher Hourigan • 4 Sep 2024
MRD as a surrogate endpoint for AML therapy
1:58
MRD as a surrogate endpoint for AML therapy
Christopher Hourigan • 4 Sep 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals